CagriSema
Also called Semaglutide + cagrilintide, Cagrilintide/semaglutide 2.4/2.4
Subcutaneous (under the skin)Human study reference
Research reference
Human study
REDEFINE 1 combination trial
Once-weekly cagrilintide/semaglutide, targeting 2.4 mg of each; separate single-agent and placebo groups
68 weeks
REDEFINE 1, NEJM (2025) ↗When results may show
- When change was measured
- Weight was assessed at week 68. Trial-product adherence and dose flexibility affect the reported estimates.
- When to assess
- 68 weeks
- Conditions and limitations
- Adults with obesity or overweight and a related condition, without diabetes. A trial coadministration product does not verify a seller's combined vial, ratio, stability or mixing instructions.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: REDEFINE 1, NEJM (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
0.5–4.8 mg of CagriSema per administration, worked out from the components rather than quoted from a study of the blend.
What is in a 4.8 mg CagriSema vial
| Component | Share | Per vial |
|---|---|---|
| Semaglutide | 50% | 2.4 mg |
| Cagrilintide | 50% | 2.4 mg |
Every draw has these same proportions.
Modelled level — once a week
One curve per component: the components clear at very different rates.
Semaglutide (in CagriSema)Cagrilintide (in CagriSema)
Where these numbers come from
- REDEFINE 1, NEJM (2025)A trial coadministration product does not verify a seller's combined vial, ratio, stability or mixing instructions.
Next steps
CagriSema beginner guideOpen CagriSema planning worksheetEstimate CagriSema vial costTrack CagriSema notes